| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Xaluritamig | AMG-509 | Phase 3 Clinical | Amgen Inc, Xencor Inc | Castration-Sensitive Prostate Neoplasms; Hormone-Sensitive Prostate Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sarcoma, Ewing | Details |
| 89Zr-DFO-MSTP2109A | Phase 2 Clinical | Genentech Inc, Memorial Sloan Kettering Cancer Center | Prostatic Neoplasms | Details | |
| STEAP1 CART Cell Therapy(PromiCell) | Phase 2 Clinical | Fred Hutchinson Cancer Research Center, PromiCell Therapeutics Inc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details | |
| PRO CAR-201A | PRO CAR-201A | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Prostatic Neoplasms, Castration-Resistant | Details |
| ABBV-969 | ABBV-969; ABBV969 | Phase 1 Clinical | Abbvie Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| ADRX-0405 | ADRX-0405 | Phase 1 Clinical | Adcentrx Therapeutics Inc | Neoplasms; Solid tumours | Details |
| DXC-008 | DAC-008; DXC-008 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Prostatic Neoplasms; Sarcoma, Ewing; Solid tumours | Details |